Related Experiment Video
Updated: Aug 13, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.2K
A multimodal fusion method for Alzheimer's disease based on DCT convolutional sparse representation.
Guo Zhang1,2, Xixi Nie3, Bangtao Liu2
1School of Communication and Information Engineering, Chongqing University of Posts and Telecommunications, Chongqing, China.
Frontiers in Neuroscience
|January 23, 2023
Summary
This study introduces a new multimodal fusion algorithm for Alzheimer's disease (AD) diagnosis using discrete cosine transform (DCT) convolutional sparse representation, improving image contrast and detail retention for better diagnostic insights.
Area of Science:
- Medical Imaging
- Artificial Intelligence
- Neuroscience
Background:
- Multimodal medical imaging, combining MRI and PET, is crucial for Alzheimer's disease (AD) diagnosis.
- Traditional sparse representation-based fusion methods suffer from energy loss, low contrast, and spatial inconsistency.
Purpose of the Study:
- To propose a novel multimodal fusion algorithm for AD diagnosis.
- To address limitations of existing fusion techniques, enhancing diagnostic accuracy.
Main Methods:
- The proposed algorithm utilizes multi-scale Discrete Cosine Transform (DCT) decomposition of source images.
- Sparse coefficients are optimized using the Alternating Directional Method of Multipliers (ADMM).
- Fused images are reconstructed using an improved L1 parametric rule and Novel Sum-Modified Spatial Frequency (NMSF).
Main Results:
- The method demonstrates significant improvements in contrast enhancement.
- It effectively retains crucial texture and contour information in fused images.
- Experimental results validate the algorithm's superior performance.
Conclusions:
- The DCT convolutional sparse representation algorithm offers a robust solution for multimodal medical image fusion in AD diagnosis.
- This approach enhances image quality, supporting more accurate and reliable diagnostic outcomes.
Related Concept Videos
Alzheimer's Disease: Overview
597
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
597
Alzheimer's Disease: Treatment
238
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
238

